France’s competition watchdog has blocked a distribution rights deal between Vivendi’s Canal Plus and Qatar-controlled beIN Sports, delivering a blow to billionaire businessman Vincent Bollore’s efforts to revive the French pay-TV channel.
Media and shipping tycoon Bollore had bet heavily on the exclusive 1.7 billion euro ($1.93 billion) five-year deal for sports content to stem a subscriber exodus that has accelerated since he took the helm of Vivendi’s board in 2014 with a vow to cut costs and reshape Canal Plus.
“The duopoly that would have represented Canal Plus and beIN Sports would have controlled 80 percent of sports rights” in France, the competition authority’s president, Bruno Lasserre, said after announcing the veto.
Such market dominance was considered potentially detrimental to consumers and internet providers that distribute beIN Sports channels.
“Bollore will have to work on other options to restore Canal Plus’ profitability: increase subscription prices, acquire companies to improve content offerings, keep on cutting costs,” said Stephane Beyazian, an analyst at Raymond James.
Vivendi’s shares were down 1.38 percent at 16.40 euros by 1451 GMT, against a 0.77 percent decline for France’s CAC 40 blue-chip index.
Bollore has pledged to turn around the pay-TV channel, which was founded 32 years ago and has let slip a commanding market position that was forged by offering coded movies, soccer and other popular sports and late-night pornography.
His first decisions to fire the channel’s top management, cut free content and put cult satirical puppet show “Les Guignols” behind a pay wall, reduced to a weekly edition, came in for fierce criticism in the media and on social media.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas